COVA322 is a bispecific TNF/IL-17A inhibitor that was designed by Covagen for the treatment of inflammatory diseases including psoriasis, psoriatic arthritis, and rheumatoid arthritis [2
]. Structurally COVA322 is a fusion protein containing an antibody that binds to TNF (in this case the light chain of adalimumab
) and a Fyn SH3-derived protein (Fynomer) that binds to IL-17A [1
]. The fusion protein was produced in transiently transfected Chinese hamster ovary (CHO) cells. COVA322 was able to simultaneously bind TNF and IL-17A.
Clinical development of COVA322 was discontinued due to an unacceptable safety profile that was detected in Phase 1 trial.